Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
2364554-48-1CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1IOVAZWDIRCRMTM-OAHLLOKOSA-NAficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.
Breast Feeding; Lactation; Milk, Human; Cardiovascular Agents
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Liver test abnormalities are infrequent in patients treated with myosin inhibitors. In publications of placebo-controlled trials of aficamten, results of serum aminotransferases, alkaline phosphatase, and bilirubin levels were usually not mentioned. However, none of the studies listed serious hepatic adverse events and there were no deaths from liver failure. The FDA’s review of the pre-registration data on safety and efficacy of aficamten mentions that ALT elevations above 3 times the ULN occurred in 2.1% of patients receiving aficamten but in none of the controls. Nevertheless, there were no instances of clinically apparent liver injury with symptoms or jaundice. Clinical experience with aficamten therapy has been limited, but ongoing trials have supported its hepatic safety.
Aficamten exhibits a dose-dependent reduction in left ventricular contractility, resulting in significant improvements in LVOT obstruction and heart failure symptoms. Pharmacokinetically, aficamten has a half-life of approximately 3.4 days in humans, reaching steady-state concentrations within two weeks. In clinical trials, reductions in the LVOT gradient (LVOT-G) were observed within two weeks of initiating treatment and sustained through Week 24. At Week 24, the mean change from baseline in resting and Valsalva LVOT-G was -35 mmHg and -48 mmHg, respectively, for the aficamten group, compared to +4 mmHg and +2 mmHg, respectively, for the placebo group. Beyond hemodynamic changes, aficamten induces favorable cardiac remodeling. A cardiac magnetic resonance (CMR) substudy demonstrated significant reductions in left ventricular mass index, maximal wall thickness, and left atrial volume index after 24 weeks of treatment, alongside substantial declines in N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I. Consistent with its mechanism, aficamten decreases left ventricular ejection fraction (LVEF); at Week 24, the mean change from baseline in LVEF was -7% in the aficamten group versus -2% in the placebo group. The drug's effects are reversible: four weeks after discontinuation of treatment, LVEF and Valsalva LVOT-G returned to baseline.
Aficamten is an oral, selective, and allosteric cardiac myosin inhibitor designed to directly target the underlying hypercontractility associated with hypertrophic cardiomyopathy (HCM). It binds reversibly to a distinct allosteric pocket on the beta-cardiac myosin motor domain, stabilizing the myosin in a specific conformation known as the "super-relaxed" or weak actin-binding state. By locking myosin heads in this state, aficamten slows the rate of phosphate release during the ATP hydrolysis cycle, which prevents the conformational changes required for myosin to transition into the force-generating, strongly actin-bound state. This action effectively decreases the number of active actin-myosin cross-bridges participating in the contractile cycle, thereby reducing the force generated by myosin at the cardiac sarcomere and attenuating left ventricular outflow tract (LVOT) obstruction.
2364554-48-1DTXSID501358934CHEMBL4847050Aficamten is extensively metabolized in humans, primarily through CYP2C9 with contributions by CYP3A, CYP2D6, and CYP2C19. Aficamten is primarily metabolized to two pharmacologically inactive metabolites, CK-3834282 and CK-3834283, that circulate at approximately 56% and 103% of parent in plasma, respectively. Inactive metabolites are further biotransformed via various reactions such as glucuronidation, sulfonation, microbiota-mediated reduction, and amide hydrolysis.
Aficamten exposure increases dose proportionally following single doses of 1 mg to 75 mg and multiple once daily doses of 5 mg to 20 mg. Geometric mean accumulation ratios for aficamten were similar across dose levels and ranged from 4.6 to 4.8. Steady state is predicted to be reached following approximately 17 days of once daily dosing of aficamten in patients with oHCM. Tmax ranges from 1.5 to 2.0 hours. Aficamten is rapidly absorbed after oral administration. The bioavailability of aficamten after oral administration is unknown.
Following a single 20 mg radiolabeled dose of aficamten, 32% (0.06% unchanged aficamten) was excreted in urine and 58% (5.1% unchanged aficamten) was excreted in feces.
The volume of distribution is 313 L. The blood to plasma ratio of aficamten was 0.94.
The total clearance is 2.6 L/hr and the renal clearance is <0.1% of total clearance.